CI-AKI in Patients With Stable CAD and Comorbidities. Are we Doing Better?
Completed
- Conditions
- Stable AnginaAcute Kidney InjuryContrast-induced Nephropathy
- Interventions
- Procedure: Iodinated contrast media
- Registration Number
- NCT04014153
- Brief Summary
Patients aged 18-89 with stable CAD and comorbidities receiving optimal medical treatment requiring PCI with iodinated contrast media.
The aim of the study is to assess the prevalence of contrast-induced AKI in 2012-2013 and 2017 cohorts and to evaluate the potential risk factors of CI-AKI to better guide the prevention in patients of higher risk.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 1023
Inclusion Criteria
- Informed consent
- Male and female patients 18 y. o. and older
- Verified stable coronary artery disease (CAD)
- Receiving optimal medical treatment and requiring percutaneous coronary intervention (PCI) with iodinated contrast media
Exclusion Criteria
- Pregnancy, lactation
- Conditions affecting the prognosis (kidney failure, liver failure, oncology)
- Acute coronary syndrome (ACS)
- Stroke
- Contraindications to PCI
- Therapy with nephrotoxic drugs during the enrolment which cannot be stopped
- Refusal to sign the informed consent
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Group 1 (5-year prognosis) Iodinated contrast media - Group 2 (1-year prognosis) Iodinated contrast media -
- Primary Outcome Measures
Name Time Method GI bleeding 5 years Overall mortality 5 years Stroke 5 years CABG 5 years CABG after PCI at enrolment
PCI 5 years Repeat PCI after the enrolment
Cardiovascular mortality 5 years Myocardial infarction 5 years
- Secondary Outcome Measures
Name Time Method